2 "STRONG BUY" Penny Stocks that offer massive potential gains....Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 (USD) per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering. However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts. Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. The platform steered us towards two tickers sporting share prices under $5 and “Strong Buy” consensus ratings from the analyst community. Not to mention substantial upside potential is on the table.
Immutep (IMMP)The second penny stock we’ll check out is Immutep, a clinical-stage biopharma company engaged in developing new immunotherapies for cancer and autoimmune disorders. The company is using Lymphocyte Activation Gene-3, or LAG-3, as a base for its therapeutic research. LAG-3 is a cell surface molecule with an immune regulation role. Immutep has several clinical-stage research lines based on LAG-3.The company’s lead drug candidate, Eftilagimod alpha (efti, IMP321), is being assessed in combination with PD-1/PD-L1 agents or chemotherapy in numerous clinical trials in metastatic breast cancer, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, solid tumors, melanoma, and Covid-19 diseases. The second asset IMP761 is at the preclinical stage for autoimmune disease.Based on the strength of data from Immutep’s key trials – Phase 2b AIPAC trial in metastatic breast cancer (mBC) and Phase 2 TACTI-002 trial in 1st line non-small cell lung cancer patients and 2nd line head and neck cancer patients, Immutep has expanded the clinical development of efti to later stage settings. The company is expected to start 3 new trials in 2022.Among the bulls is Ladenburg’s 5-star analyst Ahu Demir who writes: “In our view, Immutep is one of the most diverse players in the LAG-3 arena. The company has shown compelling data in multiple indications. Immutep is not only pursuing multiple opportunities in cancer including head and neck squamous cell carcinoma (HNSCC), metastatic breast cancer, and non-small cell lung cancer (NSCLC) but also in advanced stages of development versus competitors and also tapping into autoimmune disease.”The analyst summed up, “Given the current market cap… we see attractive value creation and upside potential for IMMP stock, with also upcoming key potential catalysts in 2H21/1H22.”Demir’s comments back up her Buy rating on the shares, and her $8.30 price target implies a one-year upside of ~122%. (To watch Demir’s track record, click here)Overall, Immutep gets a unanimous Strong Buy from the Wall Street analysts, with 3 recent reviews all in agreement that the stock is a Buy. The shares are priced at $3.70 with an average price target of $8.43, slightly more bullish than Demir’s and suggesting an upside of ~125% for the year ahead. (See IMMP Stock analysis on Tipranks)
To view the full article go to:https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-offer-massive-potential-gains/IMO
DYOR
Good luck to ALL holders.
(20min delay)